Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 17/20 | 0.40 |
| ▸ | GSK3B | P49841 | 3/20 | 0.40 |
| ▸ | CDK9 | P50750 | 13/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK7 | P50613 | 1/20 | 0.34 |
| ▸ | CCNH | P51946 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30716274 | 0.82 | CDK2 (0.45) | CDK2GSK3BCDK9CDK5CDK5R1 | |
| SCHEMBL15238119 | 0.81 | CDK2 (0.40) | CDK2GSK3BCDK9CDK5CDK5R1 | |
| SCHEMBL15245996 | 0.81 | CDK2 (0.40) | CDK2GSK3BCDK9CDK5CDK5R1 | |
| SCHEMBL15224593 | 0.80 | CDK2 (0.40) | CDK2GSK3BCDK9CDK5CDK5R1 | |
| SCHEMBL15224594 | 0.80 | CDK2 (0.40) | CDK2GSK3BCDK9CDK5CDK5R1 | |
| SCHEMBL15224590 | 0.80 | CDK2 (0.39) | CDK2GSK3BCDK9CDK5CDK5R1 | |
| SCHEMBL15242607 | 0.79 | PDE1C (0.43) | CDK2GSK3BCDK5CDK5R1 | |
| SCHEMBL15242603 | 0.79 | CDK2 (0.37) | CDK2GSK3BCDK9CDK5CDK5R1 | |
| SCHEMBL15242630 | 0.79 | CDK2 (0.39) | CDK2GSK3BCDK9CDK5CDK5R1 | |
| SCHEMBL15242721 | 0.78 | CDK2 (0.37) | CDK2GSK3BCDK9CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096608-B2 | Pharmaceutically active pyrazolo-triazine derivatives | LEAD DISCOVERY CENTER GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20150111873-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111873-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES | PAK5, STK35, TESK2 | CDK2 468/4885GSK3B 418/4885CDK9 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.